Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Last 14 days
A Prospective, Phase 2 Clinical Trial of 177Lu-P17-088 Therapy in Patients With Metastatic Androgen Pathway Modulation Resistant Prostate Cancer
Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases From Gastroenteropancreatic Neuroendocrine Tumors
Prospective, Phase 2 Clinical Trial of Low-dose 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
68Ga-P16-093 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI, a Phase 2 Clinical Trial
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)